X4 Pharmaceuticals

X4 is developing drugs that target the CXCR4 pathway, which plays a role in the way that the immune system patrols the body to seek out and destroy pathogens. The biotech was started in 2012 by executives with ties to Genzyme. Its CEO, Paula Ragan, is also a Genzyme veteran.